On June 13, 2011, Takeda, the maker of diabetes drugs Actos (pioglitazone) and Competact (pioglitazone and metformin) announce the French regulatory authorities informed it that they intended to suspend the use of the medications in the country. The move would mean doctors could no longer prescribe the drug products to new patients.
The ban on pioglitazone-containing medications was based on a study that showed an increased risk of bladder cancer in patients treated with pioglitazone for longer than a year. A pan-European review of pioglitazone safety began in March 2011.
In the United States, Takeda is funding a 10-year epidemiological study that began in 2002.
Our law firm holds drug manufacturers accountable for drugs’ adverse effects, and strives to keep residents of North Carolina and Virginia updated when it hears of allegedly defective drugs. Contact Shapiro & Appleton if you or a loved one suffers injuries from Actos.
LC